Arcus Biosciences, Inc.

Direct answer

Arcus Biosciences, Inc. is publicly traded on NYSE under the ticker RCUS.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1...

Can you invest in Arcus Biosciences, Inc.?

Yes. Arcus Biosciences, Inc. is publicly traded on NYSE under the ticker RCUS.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Arcus Biosciences, Inc.

Detailed equity research is provided by MarketSnap.